These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34229728)

  • 1. TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis.
    Cole M; Yap C; Buckley C; Ng WF; McInnes I; Filer A; Siebert S; Pratt A; Isaacs JD; Stocken DD
    Trials; 2021 Jul; 22(1):433. PubMed ID: 34229728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial.
    Siebert S; Pratt AG; Stocken DD; Morton M; Cranston A; Cole M; Frame S; Buckley CD; Ng WF; Filer A; McInnes IB; Isaacs JD
    Medicine (Baltimore); 2020 Jun; 99(26):e20458. PubMed ID: 32590730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
    Liu F; Walters SJ; Julious SA
    BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.
    Thygesen H; Dragalin V; Whitehead A; Whitehead J
    Pharm Stat; 2012; 11(6):476-84. PubMed ID: 23011957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example.
    Ryan EG; Bruce J; Metcalfe AJ; Stallard N; Lamb SE; Viele K; Young D; Gates S
    BMC Med Res Methodol; 2019 May; 19(1):99. PubMed ID: 31088354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
    Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
    Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
    Wang Y; Travis J; Gajewski B
    BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
    Liu R; Lin J; Li P
    Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.
    Berry SM; Spinelli W; Littman GS; Liang JZ; Fardipour P; Berry DA; Lewis RJ; Krams M
    Clin Trials; 2010 Apr; 7(2):121-35. PubMed ID: 20338905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
    Ewings S; Saunders G; Jaki T; Mozgunov P
    BMC Med Res Methodol; 2022 Jan; 22(1):25. PubMed ID: 35057758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.